APA (7th ed.) Citation

Taguchi, S., Kawai, T., Ambe, Y., Kishitani, K., Sugimoto, K., Miyakawa, J., . . . Yamada, D. (2023). Enfortumab vedotin versus platinum rechallenge in post‐platinum, post‐pembrolizumab advanced urothelial carcinoma: A multicenter propensity score‐matched study. International Journal of Urology, 30(12), 1180. https://doi.org/10.1111/iju.15300

Chicago Style (17th ed.) Citation

Taguchi, Satoru, et al. "Enfortumab Vedotin Versus Platinum Rechallenge in Post‐platinum, Post‐pembrolizumab Advanced Urothelial Carcinoma: A Multicenter Propensity Score‐matched Study." International Journal of Urology 30, no. 12 (2023): 1180. https://doi.org/10.1111/iju.15300.

MLA (9th ed.) Citation

Taguchi, Satoru, et al. "Enfortumab Vedotin Versus Platinum Rechallenge in Post‐platinum, Post‐pembrolizumab Advanced Urothelial Carcinoma: A Multicenter Propensity Score‐matched Study." International Journal of Urology, vol. 30, no. 12, 2023, p. 1180, https://doi.org/10.1111/iju.15300.